Spark Therapeutics Leadership to Present at Three Upcoming Healthcare Investor Conferences -, NewsCenter17, StormCenter17, Central Illinois News-

Spark Therapeutics Leadership to Present at Three Upcoming Healthcare Investor Conferences

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact

SOURCE Spark Therapeutics

PHILADELPHIA, June 2, 2014 /PRNewswire/ -- Spark Therapeutics, Inc., a late-stage gene therapy company developing treatments for a wide range of rare, debilitating diseases, announced today that company leadership will present at three healthcare investor meetings in June. 

  • 2014 Jefferies Global Healthcare Conference, New York City, June 5
    Jeffrey D. Marrazzo, co-founder and CEO of Spark, will present on Spark's leadership in the advancement of potentially curative, one-time gene therapies.
  • Jefferies Gene Therapy Summit, Boston, June 16
    Marrazzo will present on the company's expertise in ophthalmology.   
  • Piper Jaffray GenomeRx Symposium, New York City, June 23
    Marrazzo will present along with Katherine A. High, M.D. and J. Fraser Wright, Ph.D., co-founders and scientific advisors to Spark. The three will participate in multiple panels, including discussions of genomic-based ophthalmologic treatments and regulatory needs in gene therapy clinical development.

About Spark Therapeutics, Inc.

Spark Therapeutics, Inc., is developing curative, one-time gene therapy products with the potential to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark's lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials with the potential to be the first approved gene therapy in the United States, and the first treatment to address the significant unmet needs of patients living with blindness due to inherited retinal dystrophies. Additionally, the company has clinical and preclinical programs in other inherited retinal dystrophies and hematological disorders, and a proprietary manufacturing platform that has successfully supported human gene therapy trials across diverse therapeutic areas and routes of administration. Spark's founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines. To learn more visit  

For information contact:
Jessica Rowlands
Feinstein Kean Healthcare

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

904 South Side Drive
Decatur, IL 62521
Primary Phone: 217-424-2500
Primary Email:

All content © Copyright 2000 - 2014, WorldNow and WAND. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms